| Name | Title | Contact Details |
|---|---|---|
Giovanni Sosa |
Director Security Architect | Profile |
Marcio Souza |
Chief Operating Officer | Profile |
Benjamin Zaborenko |
Senior Director, IT Security | Profile |
TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.
AVI BioPharma, Inc. is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
GTx, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
TEK Solutions Inc is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.